Navigation Links
EpiCept Reports Second Quarter 2013 Operating and Financial Results
Date:7/31/2013

tibody with a drug-loaded nano-particle.
  • AmiKet™ -  a prescription topical analgesic cream designed to provide long-term relief from the pain of peripheral neuropathies, which affects more than 15 million people in the U.S.  IPI will continue EpiCept's efforts to out license the product candidate for Phase III development and commercial marketing for the treatment of chemotherapy-induced peripheral neuropathic pain (CIPN) and possibly other peripheral neuropathies.  AmiKet has obtained Fast Track status for the treatment of CIPN and is eligible for an FDA Special Protocol Assessment.  AmiKet has also been granted orphan drug status for the treatment of post-herpetic neuralgia.
  • Crolibulin -  a vascular disruption agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.  In December 2010 the National Cancer Institute initiated a Phase Ib/II trial for crolibulin to assess safety and efficacy in combination with cisplatin in patients with anaplastic thyroid cancer.  The Phase I safety portion of the trial completed in early 2013, and the results were presented at the May 2013 ASCO meeting in Chicago.  Immune believes that crolibulin may be a candidate for use with its NanomAb technology.
  • IPI will have dual headquarters in Herzliya-Pituach, Israel and in the New York City area, with research laboratories in Rehovot, Israel.  Daniel Teper, PharmD, Chief Executive Officer of Immune Pharmaceuticals Ltd., will be IPI's Chairman and CEO.  Dr. David Sidransky, Director of Head and Neck Research Division, Professor of Oncology at the Johns Hopkins School of Medicine, and a former Vice Chairman of the Board of Directors of ImClone Systems, will be the Vice Chairman of the Board.  The board of directors of the combined company will consist of Dr. Daniel Teper, Dr. David Sidransky, the remainder of the current board of directors of Immune, which co
    '/>"/>

    SOURCE EpiCept Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    6. Pharmasset Reports Fiscal Year End 2011 Financial Results
    7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/1/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/tdw3ss/2015_strategies ) has ... in the UK Flow Cytometry Market" report ... a comprehensive analysis of the UK flow cytometry ... the French flow cytometry practice, as well as ... with significant market impact during the next five ...
    (Date:6/1/2015)... -- Hutchison China MediTech Limited ("Chi-Med") ... ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, presented ... trial of HMP,s c-Met inhibitor savolitinib (AZD6094) combined ... lung cancer ("NSCLC"). AZD9291 is AstraZeneca,s ... (EGFR). Preliminary data on the activity of AZD9291 ...
    (Date:5/31/2015)... The most heavily attended and popular session at ... Meeting – “The Plenary Session Including the Science of ... immunotherapy experts and members of the Society for Immunotherapy ... of the Department of Immunology at the University of ... received the Science of Oncology Award. The Science of ...
    (Date:5/30/2015)... 2015 The Cholangiocarcinoma Foundation (CCF), ... bile duct cancer, announced today the first grant ... , The Foundation has awarded 5 ... country to raise awareness about cholangiocarcinoma and inspire ... that opens new pathways for diagnosis and drug ...
    Breaking Biology Technology:Strategies in the UK Flow Cytometry Market 2015 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3SITC Reports on Immunotherapy Insights and Data Featured at ASCO Plenary Session 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3
    ... system, described as a breakthrough advancement in breast imaging, ... Drug Administration. , ,The system offers more evidence that ... tools that enable higher quality images for the detection ... GE Healthcare said the Senographe Essential system ...
    ... we asked William Yasnoff, founder of the eHealthTrust initiative, why ... that today are fractured and limited. , , ... William Yasnoff Yasnoff is a speaker at ... deliver a presentation titled "A New Patient-Centric and Sustainable Approach ...
    ... Madison, Wis. The Wisconsin Technology Council ... legislature with statewide membership arms, has announced eight additions ... have three-year terms and will join a board that ... business technology community. Electees include four technology organization leaders: ...
    Cached Biology Technology:FDA approves advanced digital mammography system 2Interview: Dr. William Yasnoff on health records, part 2 2Interview: Dr. William Yasnoff on health records, part 2 3Interview: Dr. William Yasnoff on health records, part 2 4Interview: Dr. William Yasnoff on health records, part 2 5Interview: Dr. William Yasnoff on health records, part 2 6
    (Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
    (Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
    (Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
    Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
    ... free. But we'd all agree it's not worthless. So, ... , In 1997, the University of Vermont's Robert Costanza ... per year in a now-famous paper in the journal ... services" has bloomed. This young discipline studies how nature--through ...
    ... developed the first-ever genomic test to predict which patients ... and which patients can avoid the toxic regimen of ... save thousands of lives each year by recommending chemotherapy ... the test's developers at Duke's Institute for Genome Sciences ...
    ... therapy extends average life expectancy and decreases recurrences of ... lung cancer, according to researchers at Rhode Island Hospital. ... seven years, the median survival rate at three years ... months when thermal ablation was followed by radiation for ...
    Cached Biology News:What's nature worth? New computer models tell all 2First-ever genomic test predicts which lung cancer patients need chemotherapy to live 2First-ever genomic test predicts which lung cancer patients need chemotherapy to live 3First-ever genomic test predicts which lung cancer patients need chemotherapy to live 4Combined treatment extends life expectancy for lung cancer patients 2Combined treatment extends life expectancy for lung cancer patients 3
    ... ( Abpromise for all tested ... Synthetic peptide: IGPEVPDDRDFEPS conjugated to KLH, ... Human Decorin (fragment 36-49 of the ... Entrez GeneID: 1634 ...
    GLP expression profiling service on the Affymetrix platform. Starting material can be blood, tissue or RNA. 5 day turnaround. Standard and custom post analyses of microarray data available....
    ... a fluorescent microscopy-based imaging system that accurately ... automatically calculates cell viability, in a single ... the variability associated with the subjective interpretation ... the EasyCount ViaSure Kit, up to six ...
    In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
    Biology Products: